XenoTherapeutics Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 12

Employees
  • Latest Deal Type
  • Series A

  • Investors
  • 4

XenoTherapeutics General Information

Description

Operator of a biotechnology research and development company intended to further the advancement of the science of xenotransplantation through education, research, development, and clinical testing toward an eventual practical therapeutic use for the public benefit. The company focuses on product discovery and preclinical testing to de-risk and optimize therapeutic candidates while decreasing the time to market, enabling medical researchers to get access to an affordable, safe and plentiful treatment whenever necessary.

Contact Information

Website
www.xenotx.org
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 359 Newbury Street
  • 5th Floor, Suite 526
  • Boston, MA 02115
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XenoTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 17-May-2021 Completed Pre-Clinical Trials
3. Grant 01-Mar-2017 Completed Pre-Clinical Trials
2. Grant 27-Jan-2017 $10K Completed Pre-Clinical Trials
1. Grant 19-May-2016 Completed Startup
To view XenoTherapeutics’s complete valuation and funding history, request access »

XenoTherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology research and development company intended to further the advancement of the science of xenot
Biotechnology
Boston, MA
12 As of 2021
00000000000

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000 000000000
New York, NY
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

XenoTherapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Egenesis Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 Venture Capital-Backed New York, NY 00 0000 00000000000 0000
000000 00000000000 Formerly VC-backed Silver Spring, MD 000 00000 0000 00000
000000000 Corporation Winston-Salem, NC 000000000000
To view XenoTherapeutics’s complete competitors history, request access »

XenoTherapeutics Patents

XenoTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220053739-A1 Immunologically compatible cells, tissues, organs, and methods for transplantation for silencing, humanization, and personalization with minimized collateral genomic disruptions Pending 24-Aug-2020 00000000000
US-11424007-B2 Selection and monitoring methods for xenotransplantation Active 03-Jun-2020 00000000000 00
US-20210383892-A1 Selection and monitoring methods for xenotransplantation Active 03-Jun-2020 00000000000
CA-3133638-A1 Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same Pending 25-Mar-2019 00000000000
EP-3945799-A1 Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same Pending 25-Mar-2019 A01K67/0271
To view XenoTherapeutics’s complete patent history, request access »

XenoTherapeutics Executive Team (8)

Name Title Board Seat Contact Info
Jon Adkins Co-Founder, Chief Executive Officer & Chief Sales Officer
Curtis Cetrulo Jr. President
Mike Hager Chief Financial Officer
William Deacon Vice President of Board
You’re viewing 4 of 8 executive team members. Get the full list »

XenoTherapeutics Board Members (4)

Name Representing Role Since
Mark Nedelman Self Board Member 000 0000
Paul Barrett XenoTherapeutics Chairman 000 0000
You’re viewing 2 of 4 board members. Get the full list »

XenoTherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XenoTherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Varana Capital Hedge Fund Minority 000 0000 000000 0
Columbia Technology Ventures University 000 0000 000000 0
John Flatley Company Corporation 000 0000 000000 0
MassChallenge Accelerator/Incubator 000 0000 000000 0
To view XenoTherapeutics’s complete investors history, request access »